Acquiring Company
Pfizer
Acquired Company
Metsera
New YorkNew YorkBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmapharmaceuticalsBiotechnologyHealth CareDescription
Pfizer has announced its intention to acquire obesity startup Metsera for $7.3 billion. This acquisition marks a significant investment in the biotech sector, which has seen a resurgence in recent weeks. Metsera is known for its innovative approaches to treating obesity. This deal reflects Pfizer's strategy to enhance its portfolio in the competitive pharmaceutical market.
Who to call at Pfizer, and when
When Pfizer changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Pfizer raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Pfizer, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Pfizer. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Pfizer makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Metsera?
Metsera was acquired by Pfizer, based in New York. The deal was reported on October 13, 2025. Seagen is a biotechnology company focused on developing innovative therapies for cancer treatment. The company specializes in antibody-drug conjugates and has a portfolio of targeted therapies. Pfizer is publicly traded (PFE) and operates in Biotechnology.
When did Pfizer acquire Metsera?
Pfizer's acquisition of Metsera was reported on October 13, 2025. Pfizer has announced its intention to acquire obesity startup Metsera for $7.3 billion. This acquisition marks a significant investment in the biotech sector, which has seen a resurgence in recent weeks. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Metsera do?
Metsera is a weight-loss drug developer founded in 2022 by venture capital firm ARCH Venture and investment firm Population Health Partners. It is privately held, operating in Biotechnology, and is based in New York.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.